Highlights
- 1Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
- 2
- 3
Publications
101 publications
Funding
2 grantsView NIH portfolio on RePORTER ↗
Active
2 grants- PIR01DK139189-02Targeting Nonalcoholic Fatty Liver Disease during the reproductive period to improve women's health outcomesNational Institute of Diabetes and Digestive and Kidney Diseases · 2025–2029
- PIK23HL163486-03Nonalcoholic fatty liver disease, associated lipidomic changes, and preeclampsia riskNational Heart, Lung, and Blood Institute · 2025–2027Career
Clinical research
10 studies
Active
9 studies- PIPrevalence and implications of cholestatic gene mutations in intrahepatic cholestasis of pregnancy among a diverse U.S. cohort: a prospective study in a diverse health setting with 8000+ annual pregnancy deliveriesWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
- PIBeyond viral load: understanding how mental health and patient perspective shape hepatitis B treatment engagementWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
- PINCT07096193Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis DeltaPHASE1; PHASE2 · Gilead Sciences, Inc. · OPEN TO ACCRUAL (as of 2026)Chronic Hepatitis Delta
- PIA Pragmatic Approach to Pruritus Screening: A Descriptive Observational Study Using a Simplified Clinical ProtocolNew York Presbyterian Brooklyn Methodist Hospital · OPEN TO ACCRUAL (as of 2026)
- PIPrevalence and implications of cholestatic gene mutations in suspected intrahepatic cholestasis of pregnancy among a diverse U.S. cohort: a prospective study in a diverse health setting with 8000+ annual pregnancy deliveriesWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PINCT06780579Expanded Access Treatment Protocol for BulevirtideGilead Sciences, Inc. · OPEN TO ACCRUAL (as of 2025)Chronic Hepatitis Delta Virus Infection
- PIEvaluating the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) During PregnancyNational Center for Complementary and Integrative Health/NIH/DHHS · OPEN TO ACCRUAL (as of 2025)
- PIEvaluating prevalence, predictors and outcomes of Liver Diseases Unique to PregnancyWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PICharacterizing Epidemiology, Natural History and Management of Patients with Chronic Viral Hepatitis InfectionWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (1)
- PINCT06907290A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)PHASE2; PHASE3 · Mirum Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2026)Chronic Hepatitis D Infection
Media highlights
4 clips
- Real-World Odevixibat Data Show Pruritus Relief In Late-Onset PFICHCP Live · November 6, 2026
- Updates In Hepatitis B, Delta Hepatitis Treatments From ACGHealio · November 2, 2026
- Viral Hepatitis In Pregnancy: Updated Guidelines For HBV, Antivirals For HCVHealio Gastroenterology · October 28, 2026
- FDA Approves Bepirovirsen for Chronic Hepatitis BHCP Live · October 21, 2026
External relationships
Advisory/Scientific Board Member
Gilead Sciences, Inc. · Ipsen Pharma S.A.S. · Mirum Pharmaceuticals, Inc.
Other Interest
Gilead Sciences, Inc.